The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...

Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...